An interventional study of Cranberry beverage and Placebo beverage in Overweight/Obesity, Metabolic Syndrome and Insulin Resistance, sponsored by Laval University. Recruiting at 1 site in Canada. Open to participants aged 25 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-10.
Sponsored by Laval University · Not applicable, Interventional, and Prevention
The consumption of plant-based foods, particularly berries, has been associated with improved health due to their high content of bioactive compounds. Among these, polyphenols-especially proanthocyanidins (PACs)-may offer protective effects against chronic diseases related to overweight and obesity. Cranberries are naturally rich in PACs and may positively influence metabolic health by modulating the gut microbiota. However, their specific effects on intestinal integrity and broader metabolic outcomes remain underexplored.
The primary aim of this study is to assess the effects of cranberry supplementation on glucose metabolism, insulin sensitivity, blood lipid levels, and the composition and function of the gut microbiota in overweight and obese individuals.
This randomized, double-blind, placebo-controlled, crossover clinical trial will include two 12-week intervention periods-one with a cranberry beverage and one with a placebo-separated by a 4-week washout period and preceded by a 2-week lifestyle stabilization phase. Participants will undergo comprehensive metabolic assessments (glucose control, insulin sensitivity, lipid profile), body composition analysis, gut microbiota profiling, and liver fat imaging (MRI in a subsample of female participants). Additional evaluations will include markers of inflammation, appetite regulation, intestinal health, and lifestyle factors.
3,670 studies on the registry are indexed under Overweight; 849 are open to participants now.
This study's planned enrollment of 73 is close to the median of 73 across 3,175 interventional studies indexed under Overweight.
Browse Overweight studies →Laval University is the lead sponsor of 371 studies on the registry; 68 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Dietary Supplement: Cranberry beverage
Dietary Supplement: Placebo beverage
Daily consumption of 240 ml of cranberry beverage for 12 weeks.
Daily consumption of 240 ml of placebo beverage for 12 weeks.
Change in glucose homeostasis
Assessment of glucose concentrations during a 3-hour oral glucose tolerance test (OGTT)
Time frame: Pre and post each treatment (12 week/each)
Change in insulin secretion
Assessment of insulin a concentrations during a 3-hour oral glucose tolerance test (OGTT)
Time frame: Pre and post each treatment (12 week/each)
Change in insulin secretion
Assessment of C-Peptide concentrations during a 3-hour oral glucose tolerance test (OGTT)
Time frame: Pre and post each treatment (12 week/each)
Change in lipid profile
Assessment of triglycerides, LDL-cholesterol and HDL-cholesterol
Time frame: Pre and post each treatment (12 week/each)
Change in other measures of glucose homeostasis
Assessment of glycated hemoglobin (HbA1c)
Time frame: Pre and post each treatment (12 week/each)
Change in blood pressure
Assessment of systolic and diastolic blood pressure
Time frame: Pre and post each treatment (12 week/each)
Change in chronic inflammation
Assessment of plasma high sensitive C-Reactive Protein (hs-CRP) concentrations
Time frame: Pre and post each treatment (12 week/each)
Change in anthropometric measurements
Assessment of body mass index (BMI) using weight and height. These two measurements will be combined to calculate BMI in kg/m2
Time frame: Pre and post each treatment (12 week/each)
Change in anthropometric measurements
Assessment of waist circumference
Time frame: Pre and post each treatment (12 week/each)
Change in body composition
Assessment of changes in lean mass, fat mass and visceral fat mass (all in grams) using body composition by Dual X-ray Absorptiometry scan
Time frame: Pre and post each treatment (12 week/each)
Change in gut microbiota
Assessment of global variation of the fecal microbiota
Time frame: Pre and post each treatment (12 week/each)
Change in gut microbiota function
Assessment of short-chain fatty acid (SCFA) in feces
Time frame: Pre and post each treatment (12 week/each)
Change in fat accumulation in the liver
Evaluation of fat accumulation using magnetic resonance imaging (MRI) in a subgroup of women only.
Time frame: Pre and post each treatment (12 week/each)
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Laval University